How is Brexanolone administered?

Brexanolone is administered intravenously over a period of 60 hours as an infusion. This method of administration is specifically designed to provide a continuous delivery of the medication, allowing for stable plasma levels of the drug to effectively treat postpartum depression. The prolonged infusion period is important because it helps to maintain the therapeutic effects while minimizing any potential side effects associated with intermittent dosing.

The intravenous route is particularly advantageous for medications like brexanolone, which require careful monitoring for efficacy and safety, especially in a clinical setting. This method also ensures that the medication bypasses the gastrointestinal tract, which can be a factor in bioavailability when taking medications orally. The other options—oral, intramuscular, and inhalation—do not apply to brexanolone's approved method of delivery, making the intravenous infusion the clear correct choice.